Stephen M. Schleicher, MD, MBA, Tennessee Oncology and Community Oncology Alliance (COA) Board of Directors member, discusses what brings him back to the Community Oncology Conference year after year.
Ahead of the 2023 Community Oncology Conference, Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology and member of the Community Oncology Alliance (COA) Board of Directors, discussed what brings him back to the meeting this year after year, how COA facilitates discussion on a wide variety of initiatives, and the collaborative nature of community oncology.
Transcript
What are you excited for at this year’s Community Oncology Conference, as an attendee and a co-chair?
I’m honored to be part of the COA board of directors. They have so much influential impact on policy efforts and helping practices learn how to navigate the ever-changing external forces that can sometimes get in the way of us taking care of patients. COA is a great organization to really bring practices together to address those. And the conference is a great example of that.
Very excited this year, again, to be around colleagues from all around the country, to really focus on topics—both clinical updates in care but all these policy initiatives around PBMs [pharmacy benefits managers, step edits, EOM [Enhancing Oncology Model] coming up. How do we, as a community oncology organization, really prepare, learn from each other to move forward in an innovative effort to really help our ability to take care of patients.
I’m not going to say it’s the best conference, there are so many good conferences, but I do think COA is one of the most unique conferences at bringing thought-leaders together around clinical updates, policy, and leadership. And it’s just a great time to learn from each other.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More